Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05388695 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 30, 2025 to Mar 30, 2027 Completion date: May 1, 2025 to May 30, 2027v5 Show 1 more changeShow less
    • Completion date: May 1, 2025 to May 30, 2027
  2. Collaborator revisedv4 See this version in full on ClinicalTrials.gov ↗
  3. Site contact updated Collaborator revisedv3 Show 1 more changeShow less
    • Collaborator revised

    See this version in full on ClinicalTrials.gov ↗

  4. Interventions: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells (Biological) to Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Biological) Eligibility criteria expanded, about 3 wordsv2 Show 1 more changeShow less
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).
Trial Details
NCT Number NCT05388695
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd
Conditions 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov